Why the study?
Few patients over 75 years old are included in major ACS clinical trials, despite an increasing elderly population with comorbid pathology requiring PPCI.
Does primary percutaneous coronary intervention (PPCI) improve effectiveness and safety in elderly patients over 75 years old with acute coronary syndrome?
Does primary percutaneous coronary intervention (PPCI) improve effectiveness and safety in elderly patients over 75 years old with acute coronary syndrome?
This review summarizes the clinical evidence for primary percutaneous coronary intervention in elderly patients (>75 years) with acute coronary syndrome, a growing demographic often underrepresented in major trials.
Answers are grounded in this paper and cite their sources.
May guide individualized PPCI decisions in elderly ACS; leaves open need for dedicated RCTs in this underrepresented group.
Primary percutaneous coronary intervention (PPCI) is the gold standard of treating patients with acute coronary syndrome (ACS). The results of major clinical trials on ACS patients’ treatment are reflected in modern guidelines, where PPCI is of high evidence level and is superior to conservative therapy in long-term treatment results. Treatment of elderly patients over 75 years old is carried due to modern clinical guidelines, even though few patients of this age group are included in the studies. The increase in population average life expectancy causes the increase in number of elderly ACS patients with comorbid pathology. In its turn, it affects both the choice of treatment tactics and PPCI volume. Therefore, a study of this age group is required. The present review reflects the main clinical studies and analysis of elderly patients’ treatment
No takes yet. Share an insight, caveat, or question.
Litvinyuk et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: